Persistent negative free cash flow, which reached $6.8 million in 2024Q3, confirms a capital-intensive development phase that relies heavily on external financing.
| Cash from Operations | -15.22M | -13.81M | -17.11M | -14.14M | -10.56M | -13.54M | -7.32M | -3.55M | -716.38K | -112.2K |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -154.9% | 19.3% | -21.03% | -33.93% | 22.02% | -85% | -105.94% | -396.03% | -538.51% | - |
| Net Income | -16.49M | -15.85M | -14.86M | -18.85M | -15.27M | -14.5M | -9.46M | -3.88M | -7.39M | -219.36K |
| Depreciation & Amortization | 4.69K | 3.92K | 3.31K | 4.13K | 11.76K | 13.07K | 11.1K | 1.96K | 0 | 2.34K |
| Stock-Based Compensation | 125.36K | 187.73K | 838.96K | 1.01M | 1.2M | 1.72M | 1.29M | 477.1K | 110.24K | 119.85K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 3.82M | 2.56K | 596.11K | 498 | 337.25K | 0 | 1.58K | 270.31K | 6.48M | -62.28K |
| Working Capital Changes | -2.68M | 1.85M | -3.69M | 3.7M | 3.16M | -780.02K | 833.78K | -425.62K | 83.78K | 47.25K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 577.79K | 0 | -3.63M | 1.32M | 1.7M | 1.04M | 656.83K | 153.61K | 71.37K | 57.5K |
| Cash from Investing | -24.35K | -18.18K | -4.19K | -3.9K | -4.42K | -5.75K | -17.95K | -20.12K | 0 | 0 |
| Capital Expenditures | -24.35K | -18.18K | -4.19K | -3.9K | -4.42K | -5.75K | -17.95K | -20.12K | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 5.15M | 14.57M | 23.03M | 4.64M | 15.61M | 4.51M | 14.13M | 10.26M | 1.16M | 222.74K |
| Debt Issued (Net) | -306.89K | -297.55K | -300.81K | -438.73K | -427.7K | -477.49K | -43.08K | -35K | 300K | 121.83K |
| Equity Issued (Net) | 5.52M | 14.05M | 23.38M | 2.32M | 16.04M | 4.65M | 14.22M | 10.29M | 390.5K | 100.92K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -2.04K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -62.78K | 818.46K | -45.42K | 2.76M | 2.73K | 332.75K | -45K | 0 | 470.48K | 0 |
| Net Change in Cash | -10.1M | 739.64K | 5.91M | -9.51M | 5.05M | -9.03M | 6.8M | 6.69M | 444.59K | 110.54K |
| Free Cash Flow | -15.24M | -13.83M | -17.12M | -14.14M | -10.56M | -13.54M | -7.34M | -3.57M | -716.38K | -112.2K |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 11.21% | 19.21% | -21.02% | -33.91% | 22.02% | -84.63% | -105.28% | -398.84% | -538.51% | - |
| FCF per Share | -22.54 | -31.19 | -537.39 | -112629.70 | -232693.33 | -462542.98 | -397291.58 | -195512.89 | -39193.76 | -6138.35 |
| FCF Conversion (FCF/Net Income) | 0.92x | 0.87x | 1.15x | 0.75x | 0.69x | 0.93x | 0.77x | 0.92x | 0.10x | 0.21x |
| Interest Paid | 4.18K | 0 | 0 | 0 | 0 | 9.77K | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Single-asset clinical failure risk
As reported in financial statements, CNSP's operating cash flow frequently diverges from net income, with OCF/NI ratios fluctuating between 0.47 and 2.25, indicating that non-cash accruals and working capital swings are the primary drivers of the company's reported cash burn rather than operational efficiency.
The wide variance in the OCF/NI ratio suggests that the company's accounting losses are heavily influenced by the timing of clinical trial milestones and non-cash expenses. Investors should interpret this volatility as a sign that cash burn is dictated by external research obligations rather than predictable operational output.
Based on the provided quarterly data, CNSP consistently records negative free cash flow, with quarterly outflows reaching as high as $6.8 million, confirming that the company remains in a capital-intensive development phase with no internal cash generation to offset its ongoing research expenditures.
The lack of positive FCF is expected for a pre-revenue biotech, but the magnitude of these outflows relative to the $7.2 million cash balance warrants close monitoring. This trajectory implies that the company is entirely dependent on external financing to maintain its current clinical trial roadmap.
According to recent financial data, working capital changes have swung from a $2.6 million inflow to a $3.0 million outflow, suggesting that the company's cash position is highly sensitive to the timing of vendor payments and clinical site accruals rather than core business operations.
These erratic swings in working capital often obscure the underlying rate of cash consumption. Analysts should look past these periodic fluctuations to focus on the structural cash burn rate, which appears to be accelerating as the company approaches critical clinical trial milestones.
Financial records indicate that stock-based compensation has reached as high as $271.8K in a single quarter, which, when combined with the company's limited cash reserves, suggests that equity-based incentives are being used to preserve cash at the expense of significant shareholder dilution.
The reliance on SBC to manage liquidity is a common but risky strategy for micro-cap biotech firms. This practice may temporarily alleviate cash pressure but creates a persistent overhang that could limit future upside for equity holders if the clinical data does not provide a clear catalyst.
Quick answers to the most common questions about buying CNSP stock.
CNS Pharmaceuticals, Inc. (CNSP) generated $-13.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
CNS Pharmaceuticals, Inc. (CNSP) reported negative free cash flow of $13.8M in 2025, indicating capital requirements exceeded cash from operations.
CNS Pharmaceuticals, Inc. (CNSP) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, CNS Pharmaceuticals, Inc. (CNSP) spent $0.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.